Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 1, 2007, Pages 160-173

  Miura, Masanori ^a   Seki, Norio ^a   Koike, Takanori ^a   Ishihara, Tsukasa ^a   Niimi, Tatsuya ^a   Hirayama, Fukushi ^a   Shigenaga, Takeshi ^a   Sakai Moritani, Yumiko ^a   Tagawa, Ayako ^a   Kawasaki, Tomihisa ^a   Sakamoto, Shuichi ^a   Okada, Minoru ^a   Ohta, Mitsuaki ^a   Tsukamoto, Shin ichi ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Non amidine inhibitor; The tissue factor factor VIIa (TF FVIIa) complex; Thromboembolic disorders; Trypsin like serine protease

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; MONKEY; MOUSE; NONHUMAN;

ADMINISTRATION, ORAL; ANIMALS; BINDING SITES; BIPHENYL COMPOUNDS; BLOOD COAGULATION FACTOR INHIBITORS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FACTOR VIIA; HUMANS; HYDROGEN BONDING; LIGANDS; LIPOPROTEINS; MACACA FASCICULARIS; MALE; METHYLAMINES; MICE; MICE, INBRED ICR; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN STRUCTURE, SECONDARY; SENSITIVITY AND SPECIFICITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOPLASTIN;

MACACA FASCICULARIS;

EID: 33750941751     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.09.071     Document Type: Article

References (39)

1. Ruef J., and Katus H.A.H. Expert Opin. Investig. Drugs 12 (2003) 669
2. Morrisey J.H. Thromb. Haemost. 86 (2001) 66
3. Bouma B.N.M., and Joost C.M. Thromb. Haemost. 82 (1999) 243
4. Harker L.A., Hanson S.R., Wilcox J.N., and Kelly A.B. Haemostasis 26 (1996) 76
5. Girard T.J., and Nicholson N.S. Curr. Opin. Pharmacol. 1 (2001) 159
6. Szalony J.A., Taite B.B., Giard T.J., Nicholson N.S., and LaChance R.M. J. Thromb. Thrombolysis 14 (2002) 113
7. Senokuchi, K.; Ogawa, K. WO9941231, 1999.
8. Butenas S., Ribarik N., and Mann K.G. Biochemistry 32 (1993) 6531
9. Uchiba M., Okajima K., Abe H., Okabe H., and Takatsuki K. Thromb. Res. 74 (1994) 155
10. Semple J.E., Rowley D.C., Brunck T.K., and Ripka W.C. Bioorg. Med. Chem. Lett. 7 (1997) 315
11. Roussel P., Bradley M., Kane P., Bailey C., Arnold R., and Cross A. Tetrahedron 55 (1999) 6219
12. Jokobsen P., Ritsmar P.B., and Persson E. Bioorg. Med. Chem. 8 (2000) 2095
13. Jokobsen P., Horneman A.M., and Persson E. Bioorg. Med. Chem. 8 (2000) 2803
14. Kohrt J.T., Filipski K.J., Rapundalo S.T., Cody W.L., and Edmunds J.J. Tetrahedron Lett. 41 (2000) 6041
15. Young W.B., Kolesnikov A., Rai R., Sprengeler P.A., Leahy E.M., Shrader W.D., Sangalang J., Burgess-Henry J., Spender J., Elrod K., and Creagar L. Bioorg. Med. Chem. Lett. 11 (2001) 2253
16. Bisacchi, G. S.; Sutton, J. C., Jr.; Slusarchyk, W. A.; Treuner, U. D.; Zhao, G.; Cheney, D. L.; Wu, S. C.; Shi, Y. WO0242273, 2002.
17. Hanessian S., Therrien E., Granberg K., and Nilsson I. Bioorg. Med. Chem. Lett. 12 (2002) 2907
18. Robinson L.A., and Saiah E.M.K. Annu. Rep. Med. Chem. 37 (2002) 85
19. Parlow J.J., Stevens A.M., Stegeman R.A., Stallings W.C., Kurumbail R.G., and South M.S. J. Med. Chem. 46 (2003) 4297
20. Klingler O., Matter H., Schudok M., Bajaj S.P., Czech J., Lorenz M., Nestler H.P., Shreuder H., and Wildgoose P. Bioorg. Med. Chem. Lett. 13 (2003) 1463
21. Parlow J.J., Kurumbail R.G., Stegeman R.A., Stevens A.M., Stallings W.C., and South M.S. Bioorg. Med. Chem. Lett. 13 (2003) 3721
22. Klingler O., Matter H., Schudok M., Donghi M., Czech J., Lorenz M., Nestler H.P., Szillat H., and Shreuder H. Bioorg. Med. Chem. Lett. 14 (2004) 3715
23. Buckman B.O., Chou Y.-Ling., McCarrick M., Liang A., Lents D., Mohan R., Morrissey M.M., Shaw K.J., Trinh L., and Light D.R. Bioorg. Med. Chem. Lett. 15 (2005) 2249
24. Sagi K., Fujita K., Sugiki M., Takahashi M., Takehana S., Tashiro K., Kayahara T., Yamanashi M., Fukuda Y., Oono S., Okajima A., Iwata S., Shoji M., and Sakurai K. Bioorg. Med. Chem. 13 (2005) 1487
25. Kohrt J.T., Filipski K.J., Cody W.L., Cai C., Dudley D.A., Huis C.V., Willardsen A., Narasimhan L.S., Zhang E., Rapundalo S.T., Saiya-Cork K., Leadley R.J., and Edmunds J.J. Bioorg. Med. Chem. Lett. 16 (2006) 1060
26. Rai R., Kolesnikov A., Sprengeler P.A., Torkelson S., Ton T., Katz B.A., Yu C., Hendrix J., Shrader W.D., Stephens R., Cabuslay R., Sanford E., and Young W.B. Bioorg. Med. Chem. Lett. 16 (2006) 2270
27. Pinto D.J.P., Orwat M.J., Wang S., Fevig J.M., Quan M.L., Amparo E., Cacciola J., Rossi K.A., Alexander R.S., Smallwood A.M., Luettgen J.M., Liang L., Aungst B.J., Wright M.R., Knabb R.M., Wong P.C., Wexler R.R., and Lam P.Y.S. J. Med. Chem. 44 (2001) 566
28. Pauls H.W., and Ewing W.R. Curr. Top. Med. Chem. 1 (2001) 83
29. Schumacher W.A., Balasubramanian N., St. Laurent D.R., and Seiler S.M. Eur. J. Pharmacol. 259 (1994) 165
30. Hauptmann J., and Markwardt F. Semin. Thromb. Hemost. (1992) 200
31. Miura, M.; Seki, N.; Koike, T.; Ishihara, T.; Niimi, T.; Hirayama, F.; Shigenaga, T.; Sakai-Moritani, Y.; Kawasaki, T.; Sakamoto, S.; Okada, M.; Ohta, M.; Tsukamoto, S. Bioorg. Med. Chem. in press.
32. Coutts I.G.C., Edwards M., and Richards D.J. Synthesis (1981) 487
33. Wright S.W., Hageman D.L., Wright A.S., and McClure L.D. Tetrahedron Lett. 38 (1997) 7345
34. Miura, M,; Koike, T.; Ishihara, T.; Hirayama, F.; Sakamoto, S.; Okada, M.; Ohta, M.; Tsukamoto, S. Synth. Commun. in press.
35. In the course of our research, the X-ray crystal structure of compound 1 bound to the Des-Gla-FVIIa/sTF complex was reported by Granberg and co-workers: Granberg, K. L.; Petersen, J. F. W.; Anderson, M.; Nardi, F.; Darby, N.; Lindskog, P.; Slater, T.; Zetterberg, F. J.; Stocker, A.; Caulkett, P.; Preston, J.; Walker, R.; Gordon, C.; Fahlander, U. E. The 226th ACS National Meeting, Poster 85, New York, September 7-11, 2003. The binding mode of compound 1 is generally similar between the X-ray crystal structure and our molecular modeling.
36. 2 = 47 μM (human), >300 μM (mice), and 42 μM (cynomolgus monkeys), respectively), we planned to investigate PK profile based on inhibitory activity against human TF/FVIIa after oral administration in mice and then investigate the bleeding risk in cynomolgus monkeys by measuring the standard clotting assays (PT and APTT) and bleeding time. Bioavailability of compound 21e calculated by ex vivo study in mice is about 10%.
37. Hara T., Yokoyama A., Ishihara H., Yokoyama Y., Nagashima T., and Iwamoto M. Thromb. Haemost. 71 (1994) 314
38. Szalony and co-workers revealed that a TF/FVIIa inhibitor reduced thrombus formation on the thrombogenic surface when PT increasesd 2.2-fold. Young and co-workers also reported that a TF/FVIIa inhibitor inhibited platelet and fibrin deposition in a baboon thrombosis model when PT increased 1.13-fold:. Szalony J.A., Suleymanov O.D., Salyers A.K., Panzer-Knodle S.G., Blom J.D., LaChance R.M., Case B.L., Parlow J.J., South M.S., Wood R.S., and Nicholson N.S. Thromb. Res. 112 (2003) 167
39. Young W.B., Mordenti J., Torkelson S., Shrader W.D., Kolensmikov A., Rai R., Liu L., Hu H., Leahy E.M., Green M.J., Sprengeler P.A., Katz B.A., Yu C., Janc J.M., Elrod K.C., Marzec U.M., and Hanson S.R. Bioorg. Med. Chem. Lett. 16 (2006) 2037